Home › Research › Getting a diagnosis
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology
Ashton NJ, Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A et al.. Acta neuropathologica, 2021-02-14
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2-4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3-4 and 4, respectively. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition.
What this study adds
Evidence grade: Moderate
The record lists 588 participants. The authors report that it identified clinical stages of Alzheimer's and neuropathology equally well as blood p-tau181, so its advantage is earlier detection rather than better accuracy. Reported effect size: AUC = 0.92-0.94; AUC = 0.93; AUC = 0.89.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., et al. (2021). Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta neuropathologica. https://doi.org/10.1007/s00401-021-02275-6
Vancouver
Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta neuropathologica. 2021. doi:10.1007/s00401-021-02275-6. PMID: 33585983.
BibTeX
@article{ashton2021-33585983,
author = {Ashton, N. J. and Pascoal, T. A. and Karikari, T. K. and Benedet, A. L. and Lantero-Rodriguez, J. and Brinkmalm, G. and Snellman, A. and others},
title = {{Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology}},
journal = {Acta neuropathologica},
year = {2021},
doi = {10.1007/s00401-021-02275-6},
pmid = {33585983},
url = {https://doi.org/10.1007/s00401-021-02275-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2-4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3-4 and 4, respectively.
- To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition.
Why it matters
In this study, a new blood test for p-tau231 was already raised in people with only slight amyloid build-up (the second-lowest of four amyloid-PET bands), before the level at which an amyloid PET scan is called positive; spinal-fluid p-tau217 and blood p-tau181 rose only in higher bands. The authors report that it identified clinical stages of Alzheimer's and neuropathology equally well as blood p-tau181, so its advantage is earlier detection rather than better accuracy. It is a biomarker study comparing groups, not a treatment, and it does not show what a single person's result means.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Participants588
- Effect sizeAUC = 0.92-0.94; AUC = 0.93; AUC = 0.89
- Evidence strengthModerate
How this study scored 74/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Acta neuropathologica) |
| Journal's citation record | 3 / 4 | Acta Neuropathologica: journal h-index 287 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 588 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 714 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 102.0 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 6 / 6 | Cited 69.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 71 other studies in this library |
| Still being cited | 4 / 4 | Cited 428 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Kaj Blennow: h-index 220 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33585983) |
| Free to read | 2 / 2 | Free to read |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s00401-021-02275-6
- PubMed: 33585983
- Original source →
- Free full text: Acta Neuropathologica →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.
Later studies that cite this one
71 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.